Globus Medical jumps as analyst lifts EPS outlook after strong 2026 guidance
Globus Medical shares rose after a fresh upward revision to earnings expectations, adding to bullish sentiment following the company’s strong Q4 2025 results and raised 2026 outlook. The stock traded as high as $96.74 on April 8, 2026, versus a prior close of $90.00.
1. What’s moving the stock today
Globus Medical (GMED) moved higher Wednesday, April 8, 2026, as investors reacted to a recent round of estimate revisions that pushed projected earnings modestly higher. A widely-circulated update lifted expected EPS figures, reinforcing confidence in the company’s profit trajectory after its most recent results and forward outlook reset expectations for 2026.
2. The fundamental backdrop: guidance and execution
The latest optimism builds on the company’s February 24, 2026 update, when Globus Medical reported results for the fourth quarter and full year 2025 and issued 2026 guidance. Management’s outlook centered on continued revenue growth and improving profitability, with an EPS range that signaled operating leverage and integration progress versus prior expectations.
3. What to watch next
With the stock now back in focus, the next catalyst is whether additional estimate increases follow and whether management commentary continues to support margin expansion and cash generation through 2026. Traders will also be watching for any incremental business updates tied to procedure volumes, the company’s robotics and enabling-technology momentum, and integration execution that could validate the higher earnings path implied by the revised models.